Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

Wei, Ran; Mao, Limin; Xu, Ping; Zheng, Xiufen; Hackman, Robert M.; Mackenzie, Gerardo G.; Wang, Yuefei

doi:10.1039/c8fo01397g

Cited by 119 publications

(90 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the immunofluorescence staining for GLUT1 verified the trend of qPCR and Western blot on individual groups: Ti >TiO 2 -NTs >Ag@TiO 2 -NTs > Ag@TiO 2 -NTs+STF31 ( Figure 3B). Interestingly, Wei et al also reported that autophagy might be regulated by glucose metabolism, 56 which was consistent with our results. Autophagy is a ubiquitously conserved cellular process, which can regulate intracellular homeostasis and immunity 2 and alleviate the oxidative stress via eliminating ROS.…”

Section: Glucose Metabolism Autophagy and Macrophages Polarization supporting

confidence: 93%

Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO2 Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy

Chen¹,

Guan²,

Ren³

et al. 2020

IJN

View full text Add to dashboard Cite

Introduction: The bone regeneration of endosseous implanted biomaterials is often impaired by the host immune response, especially macrophage-related inflammation which plays an important role in the bone healing process. Thus, it is a promising strategy to design an osteo-immunomodulatory biomaterial to take advantage of the macrophage-related immune response and improve the osseointegration performance of the implant. Methods: In this study, we developed an antibacterial silver nanoparticle-loaded TiO 2 nanotubes (Ag@TiO 2-NTs) using an electrochemical anodization method to make the surface modification and investigated the influences of Ag@TiO 2-NTs on the macrophage polarization, osteo-immune microenvironment as well as its potential molecular mechanisms in vitro and in vivo. Results: The results showed that Ag@TiO 2-NTs with controlled releasing of ultra-low-dose Ag + ions had the excellent ability to induce the macrophage polarization towards the M2 phenotype and create a suitable osteo-immune microenvironment in vitro, via inhibiting PI3K/Akt, suppressing the downstream effector GLUT1, and activating autophagy. Moreover, Ag@TiO 2-NTs surface could improve bone formation, suppress inflammation, and promote osteo-immune microenvironment compared to the TiO 2-NTs and polished Ti surfaces in vivo. These findings suggested that Ag@TiO 2-NTs with controlled releasing of ultra-low-dose Ag + ions could not only inhibit the inflammation process but also promote the bone healing by inducing healing-associated M2 polarization. Discussion: Using this surface modification strategy to modulate the macrophage-related immune response, rather than prevent the host response, maybe a promising strategy for implant surgeries in the future.

show abstract

Section: Glucose Metabolism Autophagy and Macrophages Polarization supporting

confidence: 93%

Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO2 Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy

Chen¹,

Guan²,

Ren³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…In relation to EGCG, a recent study using rodent 4T1 breast carcinoma cancer cells showed that EGCG inhibits breast cancer growth, both in vitro and in vivo, associated with a reduction in glucose and lactic acid levels and GLUT1 mRNA levels in these cells [142] (Table 3).…”

Section: Quercetin and Epigallocatechin-3-gallate (Egcg)mentioning

confidence: 99%

Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds

Barbosa

Martel

2020

Cancers

View full text Add to dashboard Cite

Reprogramming of cellular energy metabolism is widely accepted to be a cancer hallmark. The deviant energetic metabolism of cancer cells-known as the Warburg effect-consists in much higher rates of glucose uptake and glycolytic oxidation coupled with the production of lactic acid, even in the presence of oxygen. Consequently, cancer cells have higher glucose needs and thus display a higher sensitivity to glucose deprivation-induced death than normal cells. So, inhibitors of glucose uptake are potential therapeutic targets in cancer. Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer death in women worldwide. Overexpression of facilitative glucose transporters (GLUT), mainly GLUT1, in breast cancer cells is firmly established, and the consequences of GLUT inhibition and/or knockout are under investigation. Herein we review the compounds, both of natural and synthetic origin, found to interfere with uptake of glucose by breast cancer cells, and the consequences of interference with that mechanism on breast cancer cell biology. We will also present data where the interaction with GLUT is exploited in order to increase the efficiency or selectivity of anticancer agents, in breast cancer cells.

show abstract

“…pancreatic and colon cancer (Baek et al, 2004;Lim et al, 2006;Kürbitz et al, 2011;Cordero-Herrera et al, 2013) (Sukhthankar et al, 2010;Kuerbitz et al, 2011;Wang et al, 2011b;Lee et al, 2012;Luo et al, 2014;Fu et al, 2019) attenuating angiogenesis MPI, ACTA1, PECAM1 lung cancer (Deng et al, 2019) inhibiting metastasis CDH1/2, CSRC, ERBB2, ESR2, MAPK8, MIR138, NFKB, PTK2, SLC22A5, SNAIL1/2, TJP1, VIM, lung, colon, breast, bladder, and prostate cancer (Shimizu et al, 2005a;Punathil et al, 2008;Sen et al, 2010;Sen and Chatterjee, 2011;Deng and Lin, 2011;Ko et al, 2013;Mukherjee et al, 2014;Li et al, 2015;Huang et al, 2016b;Luo et al, 2017) promoting apoptosis and autophagy AKT1, AP1, APAF1, ATM, BAD, BAX, BCL2/L1, BIRC5, CASP2/3/8/9, CCNB1, CDC2, CDKN1A, CYC, DIABLO, EGFR, ERBB2/3, FAS, FASLG, GDF15, JNK1/2, KRAS, MAPK1/14, MLH1, MSH2, MTCO2, MYC, NFKB, PARP1, PEG2, PGE2, PIK3CA, PRKAA2, PTEN, PTK2, SP1, TP53 pancreatic, lung, colon, head and neck, breast, and bladder cancer (Shimizu et al, 2005b;Park et al, 2009;Deng and Lin, 2011;Kang et al, 2013;Cerezo-Guisado et al, 2015;Li et al, 2016;Luo et al, 2017;Huang et al, 2017;Ni et al, 2018;Gu et al, 2018;Wei et al, 2018;Lu et al, 2019) sensitizing chemotherapy ABCG2/B1, ATP7A/B, BAX, BBC3, CASP3/7/9, CDKN...…”

Section: Discussionmentioning

confidence: 99%

Mapping Pharmacological Network of Multi-Targeting Litchi Ingredients in Cancer Therapeutics

Cao

Han

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Considerable pharmacological studies have demonstrated that the extracts and ingredients from different parts (seeds, peels, pulps, and flowers) of Litchi exhibited anticancer effects by affecting the proliferation, apoptosis, autophagy, metastasis, chemotherapy and radiotherapy sensitivity, stemness, metabolism, angiogenesis, and immunity via multiple targeting. However, there is no systematical analysis on the interaction network of "multiple ingredients-multiple targets-multiple pathways" anticancer effects of Litchi. In this study, we summarized the confirmed anticancer ingredients and molecular targets of Litchi based on published articles and applied network pharmacology approach to explore the complex mechanisms underlying these effects from a perspective of system biology. The top ingredients, top targets, and top pathways of each anticancer function were identified using network pharmacology approach. Further intersecting analyses showed that Epigallocatechin gallate (EGCG), Gallic acid, Kaempferol, Luteolin, and Betulinic acid were the top ingredients which might be the key ingredients exerting anticancer function of Litchi, while BAX, BCL2, CASP3, and AKT1 were the top targets which might be the main targets underling the anticancer mechanisms of these top ingredients. These results provided references for further understanding and exploration of Litchi as therapeutics in cancer as well as the application of "Component Formula" based on Litchi's effective ingredients.

show abstract

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

Abstract: EGCG reduces breast cancer growth through the inhibition of key enzymes that participate in the glycolytic pathway and the suppression of glucose metabolism.

Cited by 119 publications

References 69 publications

<p>Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO<sub>2</sub> Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy</p>

<p>Improved Immunoregulation of Ultra-Low-Dose Silver Nanoparticle-Loaded TiO<sub>2</sub> Nanotubes via M2 Macrophage Polarization by Regulating GLUT1 and Autophagy</p>

Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds

Mapping Pharmacological Network of Multi-Targeting Litchi Ingredients in Cancer Therapeutics

Contact Info

Product

Resources

About